Paper Review Records
全部论文审稿周期
5 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
152
天
Real-World Data on First Relapse in Multiple Myeloma: Treatment Patterns and Outcomes in Finland Using Automated Data Collection
作者
Johanna Vikkula; Kari Remes; Outi Laatikainen; Merja Utriainen; Saara Tikka; Juha Lievonen展开收起
作者单位
1. Medaffcon Oy, Espoo, Finland; 2. Turku University, Turku, Finland; 3. GSK Oy, Helsinki, Finland; 4. Helsinki University Hospital, Comprehensive Cancer Center, Helsinki, Finland展开收起
148
天
Treatment Decision-Making for Individuals with Relapsed/Refractory Chronic Lymphocytic Leukemia in the USA
作者
Catherine C. Coombs; Thomas W. LeBlanc; Katherine B. Winfree; Catherine E. Muehlenbein; Urvi Desai; Noam Y. Kirson; Ashley Holub; Alice Qu; Ellen Sears; Brian Koffman; Meghan C. Thompson展开收起
作者单位
1. University of California Irvine School of Medicine, Irvine, CA, USA; 2. Duke University School of Medicine, Durham, NC, USA; 3. Eli Lilly and Company, Indianapolis, IN, USA; 4. Analysis Group Inc., Boston, MA, USA; 5. CLL Society, Chula Vista, CA, USA; 6. Memorial Sloan Kettering Cancer Center, New York, NY, USA展开收起
304
天
BEAC Induction Regimen and Prior Thoracic Radiotherapy Increases the Risk of ASCT-Associated Pneumonitis
作者
Elina Kaprio; Anna Jokimäki; Hanne Kuitunen; Joel Kontiainen; Tuomas Selander; Taina Turpeenniemi-Hujanen; Outi Kuittinen展开收起
作者单位
1. Institute of Clinical Medicine, Faculty of Health Medicine, University of Eastern Finland, Kuopio, Finland; 2. Central Hospital of Southern Osthrobotnia, Seinäjoki, Finland; 3. Oulu University Hospital, Medical Research Center and Cancer Centre, Oulu University Hospital, Oulu, Finland; 4. Department of Oncology, Tampere University Hospital and Tampere University, Tampere, Finland; 5. Science Service Center, Kuopio University Hospital, Kuopio, Finland; 6. University of Oulu, Translational Medicine Research Unit, Oulu, Finland; 7. Kuopio University Hospital, Cancer Center, Kuopio, Finland展开收起
191
天
Anexelekto (Axl)/Mer Inhibitor Tamnorzatinib in Patients with Relapsed/Refractory Acute Myeloid Leukaemia: Results from a Phase I (Monotherapy) and Phase II (Combination with Venetoclax) Clinical Study
作者
Margaret T. Kasner; Nigel Courtenay-Luck; Courtney D. DiNardo; Sean M. Post; Praneeth Baratam; George N. Magrath; Takaaki Nakamura; Akifumi Fujii; Sergio Prados; Naoki Honda; Mary McBride; Paula Edwards-Holmes; Robert Stuart展开收起
作者单位
1. Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA; 2. Ono Pharma UK Ltd., London, UK; 3. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 4. Division of Hematology and Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA; 5. Storm Eye Institute, Medical University of South Carolina, Charleston, SC, USA; 6. Ono Pharmaceutical Co., Ltd., Osaka, Japan; 7. Ono Pharma USA, Inc., Cambridge, MA, USA展开收起
314
天
Patients with Prior Cerebral Venous Sinus Thrombosis Presenting to the Emergency Department with Neurological Symptoms: The Yield of Neuroimaging
作者
Evgeny Grishin; Ivan Budnik; Orly Efros; Omri Cohen; Gili Kenet; Sarina Levy-Mendelovich; Assaf Arie Barg展开收起
作者单位
1. Faculty of Medicinal and Health Sciences, Tel Aviv University, Tel Aviv, Israel; 2. Division of Hematology/Oncology, Department of Internal Medicine, University of Iowa, Iowa City, IA, USA; 3. Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel; 4. National Hemophilia Center, Coagulation Unit and Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Ramat Gan, Israel; 5. Department of Medicine and Surgery, University of Insubria, Varese, Italy; 6. Talpiot Sheba Leadership Program, Sheba Medical Center, Ramat Gan, Israel; 7. Departmnet of Pediatric Hematology-Oncology, The Edmond and Lily Safra Children’s Hospital, Sheba Medical Center, Ramat Gan, Israel展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天